The present disclosure relates to afucosylated anti FGFR-III2b antibody constructs, their production and and their uses as pharmaceuticals. The fucosylation site is located at Asn 297, e.g on the CH2 domain of the antibody, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.